DexCom, Inc. (NASDAQ:DXCM) Shares Bought by BOK Financial Private Wealth Inc.

BOK Financial Private Wealth Inc. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 16,967.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,923 shares of the medical device company's stock after buying an additional 10,859 shares during the quarter. BOK Financial Private Wealth Inc.'s holdings in DexCom were worth $1,355,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC boosted its position in DexCom by 11.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company's stock valued at $108,000 after buying an additional 115 shares during the period. CX Institutional acquired a new stake in shares of DexCom in the fourth quarter worth $286,000. Cerity Partners LLC increased its stake in shares of DexCom by 5,791.0% in the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company's stock worth $57,574,000 after acquiring an additional 456,097 shares during the period. Turtle Creek Wealth Advisors LLC purchased a new stake in DexCom during the fourth quarter worth $57,000. Finally, Intelligence Driven Advisers LLC purchased a new position in DexCom during the third quarter valued at $525,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $3.48 during midday trading on Friday, hitting $136.14. The stock had a trading volume of 2,413,463 shares, compared to its average volume of 2,320,460. The company has a market capitalization of $52.48 billion, a PE ratio of 103.92, a P/E/G ratio of 2.34 and a beta of 1.20. The stock has a 50 day simple moving average of $128.56 and a 200-day simple moving average of $115.58. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company's revenue was up 26.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.34 earnings per share. On average, sell-side analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 2,902 shares of DexCom stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $358,774.26. Following the sale, the executive vice president now directly owns 79,051 shares of the company's stock, valued at $9,773,075.13. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Michael Jon Brown sold 2,624 shares of the company's stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares of the company's stock, valued at $9,618,227.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 2,902 shares of the firm's stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $358,774.26. Following the sale, the executive vice president now directly owns 79,051 shares of the company's stock, valued at approximately $9,773,075.13. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 235,892 shares of company stock worth $31,252,330. 0.41% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on DXCM shares. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price target for the company. Piper Sandler upped their price target on shares of DexCom from $135.00 to $150.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 19th. Raymond James boosted their price objective on shares of DexCom from $147.00 to $151.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 23rd. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Finally, StockNews.com raised shares of DexCom from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $141.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.